Literature DB >> 19738436

Inflammation: a hidden path to breaking the spell of ovarian cancer.

Weiwei Shan1, Jinsong Liu.   

Abstract

Epithelial ovarian cancer is a highly lethal gynecological cancer for which overall prognosis has remained poor over the past few decades. A number of theories have been postulated in an effort to explain the etiology of epithelial ovarian cancer, each of which has been both applauded and doubted. Of note, these theories likely are not mutually exclusive, as they all converge more or less on the role of inflammation in promoting ovarian tumorigenesis. In this review, we describe the latest studies on the role of inflammation in the initiation and progression of epithelial ovarian cancer from three major aspects: physiological functions of a normal ovary, potential involvement of the fallopian tube in the initiation of epithelial ovarian cancer and the strong impact of the cellular microenvironment on the development of the disease.

Entities:  

Mesh:

Year:  2009        PMID: 19738436     DOI: 10.4161/cc.8.19.9590

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  20 in total

1.  The role of cytokines in UbD promoter regulation and Mallory-Denk body-like aggresomes.

Authors:  Joan Oliva; Fawzia Bardag-Gorce; Andrew Lin; Barbara A French; Samuel W French
Journal:  Exp Mol Pathol       Date:  2010-04-28       Impact factor: 3.362

2.  Does vitamin D mediate inhibition of epithelial ovarian cancer by modulating cytokines?

Authors:  S Mohapatra; A Saxena; G Gandhi; B C Koner; T Singh; P C Ray
Journal:  Clin Transl Oncol       Date:  2015-03-05       Impact factor: 3.405

3.  AXL is an essential factor and therapeutic target for metastatic ovarian cancer.

Authors:  Erinn B Rankin; Katherine C Fuh; Tiffany E Taylor; Adam J Krieg; Margaret Musser; Jenny Yuan; Kevin Wei; Calvin J Kuo; Teri A Longacre; Amato J Giaccia
Journal:  Cancer Res       Date:  2010-09-21       Impact factor: 12.701

4.  Circulating inflammation markers and risk of epithelial ovarian cancer.

Authors:  Tess V Clendenen; Eva Lundin; Anne Zeleniuch-Jacquotte; Karen L Koenig; Franco Berrino; Annekatrin Lukanova; Anna E Lokshin; Annika Idahl; Nina Ohlson; Goran Hallmans; Vittorio Krogh; Sabina Sieri; Paola Muti; Adele Marrangoni; Brian M Nolen; Mengling Liu; Roy E Shore; Alan A Arslan
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2011-04-05       Impact factor: 4.254

5.  Mixed lineage kinase 3 is required for matrix metalloproteinase expression and invasion in ovarian cancer cells.

Authors:  Yu Zhan; Widian F Abi Saab; Nidhi Modi; Amanda M Stewart; Jinsong Liu; Deborah N Chadee
Journal:  Exp Cell Res       Date:  2012-05-28       Impact factor: 3.905

6.  Potential impact of (rs 4645878) BAX promoter -248G>A and (rs 1042522) TP53 72Arg>pro polymorphisms on epithelial ovarian cancer patients.

Authors:  S Dholariya; R Mir; M Zuberi; P Yadav; G Gandhi; N Khurana; A Saxena; P C Ray
Journal:  Clin Transl Oncol       Date:  2015-07-25       Impact factor: 3.405

Review 7.  Pelvic Inflammatory Disease and the Risk of Ovarian Cancer and Borderline Ovarian Tumors: A Pooled Analysis of 13 Case-Control Studies.

Authors:  Christina B Rasmussen; Susanne K Kjaer; Vanna Albieri; Elisa V Bandera; Jennifer A Doherty; Estrid Høgdall; Penelope M Webb; Susan J Jordan; Mary Anne Rossing; Kristine G Wicklund; Marc T Goodman; Francesmary Modugno; Kirsten B Moysich; Roberta B Ness; Robert P Edwards; Joellen M Schildkraut; Andrew Berchuck; Sara H Olson; Lambertus A Kiemeney; Leon F A G Massuger; Steven A Narod; Catherine M Phelan; Hoda Anton-Culver; Argyrios Ziogas; Anna H Wu; Celeste L Pearce; Harvey A Risch; Allan Jensen
Journal:  Am J Epidemiol       Date:  2016-12-09       Impact factor: 4.897

8.  Combination therapy with atorvastatin and celecoxib delays tumor formation in a Fanconi anemia mouse model.

Authors:  Qing-Shuo Zhang; Matthew Deater; Ngoc Phan; Andrea Marcogliese; Angela Major; Eva C Guinan; Markus Grompe
Journal:  Pediatr Blood Cancer       Date:  2018-09-25       Impact factor: 3.167

9.  Ovarian epithelial-stromal interactions: role of interleukins 1 and 6.

Authors:  Kamisha T Woolery; Patricia A Kruk
Journal:  Obstet Gynecol Int       Date:  2011-06-26

10.  Phytoestrogen consumption from foods and supplements and epithelial ovarian cancer risk: a population-based case control study.

Authors:  Elisa V Bandera; Melony King; Urmila Chandran; Lisa E Paddock; Lorna Rodriguez-Rodriguez; Sara H Olson
Journal:  BMC Womens Health       Date:  2011-09-23       Impact factor: 2.809

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.